Indwelling pleural catheters for malignancy related pleural effusions

A. AUJAYEB, K. JACKSON

Respiratory and Acute Medicine Consultant, Northumbria HealthCare NHS Foundation Trust, Care of Tracy Groom, Cramlington, Northumberland, NE23 6NZ, UK

Abstract. – OBJECTIVE: Malignant Pleural Effusion (MPE) carries significant morbidity and mortality. Indwelling pleural catheters (IPC) are established in the management pathway. Large case reviews add to the evidence base regarding safety and efficacy.

PATIENTS AND METHODS: 168 patients had an IPC inserted between January 2012 and December 2018 in a large pleural centre. Data on outcomes and complications were obtained from the patients' notes, laboratory and radiographic findings. A descriptive statistical methodology was applied.

RESULTS: 168 IPCs were inserted in a predominantly male population. The overall complication rate is 13%. The incidence of any individual complication such as infection, metastatic seeding, drain displacement, and loculations are all less than previously described.

CONCLUSIONS: This case review adds to the large body of evidence that IPCs are safe and have minimal complications. Specific factors enabling this are the use of pre-operative antibiotics, the use of theatre space, and the experience of the pleural interventional physicians.

Key Words: Malignant pleural effusion, Indwelling pleural catheter.

Introduction

Malignant Pleural Effusion (MPE) confers a poor prognosis, with a median survival of 3-12 months1. MPE has a significant symptom burden, often requiring more than one pleural intervention and consuming significant resources1.

Pleural interventions consist of therapeutic thoracentesis, intercostal drain or indwelling pleural catheter (IPC) insertion with or without talc instillation and local anaesthetic (LAT) or video-assisted thoracoscopy2. A patient-centered approach is advocated2.

IPCs improve quality of life, prevent additional interventions, and reduce hospital attendance. American Association for Bronchoscopy and Intervventional Pulmonology (AABIP) guidance firmly supports IPCs3.

Northumbria Healthcare NHS Foundation Trust has a large pleural service4. Procedures performed include (LAT), IPC insertion and removal. IPC insertions also occur in dedicated procedure rooms. There is no thoracic surgery on site.

Patients and Methods

Local Caldicott approval was obtained. A retrospective study of all consecutive patients who underwent IPC placement in theatre from Jan 2012 to Dec 2018 was performed. Basic demographics and outcomes were collected. A descriptive statistical methodology was applied.

Perioperative Management

Patients with presumed MPE are referred to pleural clinics where management options are discussed, and referrals for an IPC are then made. The average waiting time is 10 working days. Pre-operative antibiotics (fluclxacillin or teicoplanin) are administered.

IPC Technique

Patients are placed in the lateral decubitus position. A thoracic ultrasound (TUS) is performed to mark the spot for incision and insertion of the Rocket® IPC™, normally at the posterior axillary line, in the 5th or 6th intercostal space. The area is sterilized and draped. 20 milliliters (mL) of bupivicaine and adrenaline (epinephrine) injection 0.5% w/v, 1 in 200,000 is administered into the intercostal space. 2 incisions are made 5 cm apart. A tract is created with straight forceps. The drain is passed through and the cuff sits midway. A di-
Indwelling pleural catheters for malignancy related pleural effusions

Post-Operative Care

A chest radiograph is not routinely obtained. On discharge, district nurses perform regular drainages according to the patient’s symptoms. Patients are discharged to the referring service.

Results

168 IPCs were inserted.

The mean patient age was 72.8 years (range 35-92, IQR 65-82). 61.3 % were male (n=103). 36 IPCs were done for mesothelioma, 48 for lung cancer, 28 for breast cancer, 23 for others such as melanomas, gastrointestinal and ovarian cancers. 13 were for non-malignant indications (unexplained chronic lymphocytic effusions, hepatic hydrothoraces, yellow nail syndrome, heart failure and chronic pleuritis).

There were no immediate complications (bleeding, pneumothorax or surgical emphysema). 162 patients (96%) had antibiotics pre-procedure. 5 patients (3%) developed pleural infections more than 30 days after insertion (4 male, 1 female, mean age 67.4 years [range 55-75]). All had antibiotic prophylaxis. 2 had contemporaneous cellulitis requiring intravenous antibiotics. 2 out of 5 pleural fluid samples were positive for methicillin-sensitive Staphylococcus aureus (MSSA). 2 received intrapleural fibrinolytics for infection clearance. 1 had a recurrent infection due to the IPC cuff being colonized: this was removed. None of these patients were receiving anti-cancer treatment. The median length of hospital stay was 4.7 days (range 3-12). 128 patients received chemotherapy with no issues. 2 (1%) patients had drain displacement. Those were removed. 1 (0.6%) patient had a cutaneous tumor extension through the IPC site. The IPC had been in for 6.2 months. No treatment was required. 14 patients (1%) developed significant loculations and non-drainage. 13 patients were given intrapleural fibrinolytics with good radiological and clinical response. 1 patient’s symptoms were palliated. 6 of the 13 patients (46%) had recurring loculations and their symptoms were palliated. The remaining 7 had their IPC removed due to pleurodesis.

Median survival from the day of insertion was 147 days (IQR 12-262). Removal rates for any reason were 36% (61 out of 168) patients. No further procedures were required.

Discussion

The overall complication rate is 13%. Individual rates are lower than described3,6,7.

3 interventional pleural physicians with significant cumulative experience place IPCs locally. Training doctors are closely supervised. National safety standards for invasive procedures (NATSIP) checklists are rigidly adhered to. TUS allows the identification of a suitable pleural space and aberrant intercostal arteries. This accounts for the lack of immediate complications.

IPC-related infection traditionally affects less than 5% of patients. Our case series corroborates this. There is no significant increase in the risk of IPC-related infection associated with systemic chemotherapy3,7. Infections are traditionally associated with skin commensals, including staph aureus species. The removal of the IPC is not usually warranted unless the tunnel is chronically infected. We administer prophylactic antibiotics pre-procedure as had previously noticed a rise in infections without8. This is the local practice. No national guidance is available. Gilbert et al9 showed that a sterile protocol, a single hospital site to perform the IPC placement and perioperative antibiotics enabled a reduction in IPC-related infection from 8.2% to 2.2% (p=0.0049) and a relative risk reduction of 73%.

Tumor extension occurred in less than 5% of cases and was in less than 1% of patients locally. It is more common in procedures such as medical thoracoscopy. There is no role for pre or post-operative radiotherapy.

Symptomatic loculations occur in 14% of all IPCs10. They are caused by the accumulation of fibrinous material from the tumor and the presence of a foreign body. Impaired fluid drainage causes increased breathlessness. Fibrinolytic therapy can improve radiological appearances and clinical outcomes. However, the recurrence rate of loculations is high10. Loculations in our cohort is lower than expected. We surmise that this is an underestimate as routine follow-up does not occur. 107 of the cohort died with the IPC in situ, and we do not know if the IPC continued to function until this time.

Our removal rates are comparable to the previous series1. 30-40% of patients will achieve spontaneous pleurodesis. This can be improved with
aggressive drainage and talc administration\(^3\). Due to local administrative and financial constraints, we do not offer this approach. We simply ask clinicians or patients to get in touch after minimal drainage from the IPC has been observed on 3 consecutive occasions. Patients are then assessed for fluid clearance with chest radiographs and TUS. A subgroup analysis of these patients is being performed and is beyond the scope of this article. We have also not discussed IPCs in benign effusions. A further limitation of our study is that we only include patients who have had IPCs in theatre, and not on the various day case units. We are currently working on a central database to track all IPC patients. We do not perform chest radiographs post-insertion; hence rates of surgical emphysema may be underestimated.

**Conclusions**

Our data add to the large body of evidence that IPCs are safe and have minimal complications. Contributing factors are the use of thoracic ultrasound, the use of pre-operative antibiotics, performing procedures in theatre, and experienced pleural physicians. Our protocol can be generalized in other hospitals to achieve similar outcomes.

**Disclosure statement**

There are no competing interests.

**Ethics statement**

Not applicable.

**Acknowledgements**

Thanks to Helen Grover, David Hopkins and Anas Al Fahad for having helped to collect the data.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

---

**References**